With the identification of novel therapeutic targets in different MPN and the movement of second-/third-line treatment upfront, the MPN therapeutic landscape is continuously changing. For Ph+ CML, additional genetic mutations are probably going to change our currently known risk stratification and determine choice of front-line treatment. In Ph- MPN, focus is on molecular response and disease modification and scientific evidence that this might actually have beneficial effect on patient outcome is gradually being gathered.

(BELG J HEMATOL 2023;14(1):10–5)